Serum cystatin C and the incidence of hypertension in type 1 diabetes mellitus

American Journal of Hypertension

Volumn 24, Issue 1, 2011, Pages 59-63

  Sahakyan, Karine ^a   Klein, Barbara E K ^a   Lee, Kristine E ^a   Tsai, Michael Y ^b   Klein, Ronald ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

blood pressure; cystatin C; epidemiology; hypertension; type 1 diabetes

Indexed keywords

ANTIHYPERTENSIVE AGENT; CYSTATIN C; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN;

ADULT; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD LEVEL; BODY MASS; CARDIOVASCULAR RISK; CONCENTRATION (PARAMETERS); DIABETIC RETINOPATHY; DIASTOLIC BLOOD PRESSURE; DISEASE DURATION; FEMALE; HAZARD RATIO; HUMAN; HYPERTENSION; INCIDENCE; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; STATISTICAL MODEL; SYSTOLIC BLOOD PRESSURE;

ADULT; BODY MASS INDEX; CYSTATIN C; DIABETES MELLITUS, TYPE 1; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; HYPERTENSION; INCIDENCE; MALE; MIDDLE AGED;

EID: 78650264993     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1038/ajh.2010.215     Document Type: Article

References (37)

1. Sprafka JM, Bender A P, Jagger HG. Prevalence of hypertension and associated risk factors among diabetic individuals. The Three-City Study. Diabetes Care 1988; 11:17-22.
2. Klein R, Klein BE, Lee KE, Cruickshanks KJ, Moss SE. The incidence of hypertension in insulin-dependent diabetes. Arch Intern Med 1996; 156:622-627.
3. Salman RA, Al-Rubeaan KA. Incidence and risk factors of hypertension among Saudi type 2 diabetes adult patients: an 11-year prospective randomized study. J Diabetes Complicat 2009; 23:95-101.
4. Janghorbani M, Amini M. Hypertension in type 2 diabetes mellitus in Isfahan, Iran: incidence and risk factors. Diabetes Res Clin Pract 2005; 70:71-80.
5. Borst-de Geus A, Borst-de Gues JG. Hypertension explained by Starling's theory of circulatory homoeostasis. Lancet 1963; 7283:677-682.
6. Guyton AC, Coleman TG, Cowley AV Jr, Scheel KW, Manning RD Jr, Norman RA Jr. Arterial pressure regulation. Overriding dominance of the kidneys in long-term regulation and in hypertension. Am J Med 1972; 52:584-594.
7. Ito S. Kidney and hypertension: role of the juxtaglomerular apparatus. Tohoku J Exp Med 1997; 181:411-429.
8. Ichihara A, Kobori H, Nishiyama A, Navar LG. Renal renin-angiotensin system. Contrib Nephrol 2004; 143:117-130.
9. Kestenbaum B, Rudser KD, de Boer IH, Peralta CA, Fried LF, Shlipak MG, Palmas W, Stehman-Breen C, Siscovick DS. Differences in kidney function and incident hypertension: the multi-ethnic study of atherosclerosis. Ann Intern Med 2008; 148:501-508.
10. Klein R, Klein BE, Moss SE, DeMets DL, Kaufman I, Voss PS. Prevalence of diabetes mellitus in southern Wisconsin. Am J Epidemiol 1984; 119:54-61.
11. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin epidemiologic study of diabetic retinopathy. II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol 1984; 102:520-526.
12. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. IX. Four-year incidence and progression of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol 1989; 107:237-243.
13. Klein R, Klein BE, Moss SE, Cruickshanks KJ. The Wisconsin Epidemiologic Study of diabetic retinopathy. XIV. Ten-year incidence and progression of diabetic retinopathy. Arch Ophthalmol 1994; 112:1217-1228.
14. Klein R, Klein BE, Moss SE, Cruickshanks KJ. The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XVII. The 14-year incidence and progression of diabetic retinopathy and associated risk factors in type 1 diabetes. Ophthalmology 1998; 105:1801-1815.
15. Klein R, Knudtson MD, Lee KE, Gangnon R, Klein BE. The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XXII the twenty-five-year progression of retinopathy in persons with type 1 diabetes. Ophthalmology 2008; 115: 1859-1868.
16. Klein BE, Klein R, McBride PE, Cruickshanks KJ, Palta M, Knudtson MD, Moss SE, Reinke JO. Cardiovascular disease, mortality, and retinal microvascular characteristics in type 1 diabetes: Wisconsin epidemiologic study of diabetic retinopathy. Arch Intern Med 2004; 164:1917-1924.
17. Lip GY, Edmunds E, Martin SC, Jones AF, Blann AD, Beevers DG. A pilot study of homocyst(e)ine levels in essential hypertension: relationship to von Willebrand factor, an index of endothelial damage. Am J Hypertens 2001; 14:627-631.
18. Brattström L, Wilcken DE. Homocysteine and cardiovascular disease: cause or effect? Am J Clin Nutr 2000; 72:315-323.
19. Wollesen F, Brattström L, Refsum H, Ueland PM, Berglund L, Berne C. Plasma total homocysteine and cysteine in relation to glomerular filtration rate in diabetes mellitus. Kidney Int 1999; 55:1028-1035.
20. Lim U, Cassano PA. Homocysteine and blood pressure in the Third National Health and Nutrition Examination Survey, 1988-1994. Am J Epidemiol 2002; 156:1105-1113.
21. Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, Kusek JW, Van Lente F; Chronic Kidney Disease Epidemiology Collaboration. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 2006; 145:247-254.
22. Hosmer DW, Lemeshow S. Special topics. In: Applied Logistic Regression, 1st edn. Wiley & Sons: New York, 1989, pp. 238-245.
23. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 1999; 18:695-706.
24. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53:457-481.
25. Stevens LA, Coresh J, Schmid CH, Feldman HI, Froissart M, Kusek J, Rossert J, Van Lente F, Bruce RD 3rd, Zhang YL, Greene T, Levey AS. Estimating GFR using serum cystatin C alone and in combination with serum creatinine: a pooled analysis of 3,418 individuals with CKD. Am J Kidney Dis 2008; 51:395-406.
26. Coll E, Botey A, Alvarez L, Poch E, Quintó L, Saurina A, Vera M, Piera C, Darnell A. Serum cystatin C as a new marker for noninvasive estimation of glomerular filtration rate and as a marker for early renal impairment. Am J Kidney Dis 2000; 36:29-34.
27. Newman DJ, Thakkar H, Edwards RG, Wilkie M, White T, Grubb AO, Price CP. Serum cystatin C measured by automated immunoassay: a more sensitive marker of changes in GFR than serum creatinine. Kidney Int 1995; 47: 312-318.
28. Willems D, Wolff F, Mekhali F, Gillet C. Cystatin C for early detection of renal impairment in diabetes. Clin Biochem 2009; 42:108-110.
29. Leung-Tack J, Tavera C, Gensac MC, Martinez J, Colle A. Modulation of phagocytosis-associated respiratory burst by human cystatin C: role of the N-terminal tetrapeptide Lys-Pro-Pro-Arg. Exp Cell Res 1990; 188:16-22.
30. Arpegård J, Ostergren J, de Faire U, Hansson LO, Svensson P. Cystatin C-a marker of peripheral atherosclerotic disease? Atherosclerosis 2008; 199:397-401.
31. Niccoli G, Conte M, Della Bona R, Altamura L, Siviglia M, Dato I, Ferrante G, Leone AM, Porto I, Burzotta F, Brugaletta S, Biasucci LM, Crea F. Cystatin C is associated with an increased coronary atherosclerotic burden and a stable plaque phenotype in patients with ischemic heart disease and normal glomerular filtration rate. Atherosclerosis 2008; 198:373-380.
32. Taglieri N, Koenig W, Kaski JC. Cystatin C and cardiovascular risk. Clin Chem 2009; 55:1932-1943.
33. Shlipak MG, Katz R, Cushman M, Sarnak MJ, Stehman-Breen C, Psaty BM, Siscovick D, Tracy RP, Newman A, Fried L. Cystatin-C and inflammatory markers in the ambulatory elderly. Am J Med 2005; 118:1416.
34. Sesso HD, Buring JE, Rifai N, Blake GJ, Gaziano JM, Ridker PM. C-reactive protein and the risk of developing hypertension. JAMA 2003; 290:2945-2951.
35. Sesso HD, Wang L, Buring JE, Ridker PM, Gaziano JM. Comparison of interleukin-6 and C-reactive protein for the risk of developing hypertension in women. Hypertension 2007; 49:304-310.
36. Bautista LE, López-Jaramillo P, Vera LM, Casas JP, Otero AP, Guaracao AI. Is C-reactive protein an independent risk factor for essential hypertension? J Hypertens 2001; 19:857-861.
37. Bautista LE, Vera LM, Arenas IA, Gamarra G. Independent association between inflammatory markers (C-reactive protein, interleukin-6, and TNF-α) and essential hypertension. J Hum Hypertens 2005; 19:149-154